开元股份(300338.SZ):罗旭东已通过大宗交易减持291.657万股
格隆汇 12 月 8日丨开元股份(300338.SZ)公布,公司近日收到公司5%以上股东罗旭东的《关于减持股份的告知函》。因个人资金需求,罗旭东通过大宗交易方式减持了291.657万股开元股份的股票,完成减持后不再持有开元股份股票。
此次减持后,罗建文、罗旭东、罗华东三父子合计持有公司股份3415.7598万股,占公司总股本比例为10.01%。待罗建文协议转让其持有的1710万股开元股份股票(占开元股份股份总数的5.01%)过户完成后,罗建文及其一致行动人的持股数合计1705.7598万股,占总股本的比例为4.9995%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.